Page last updated: 2024-11-13
fluorocoxib a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
fluorocoxib A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24884549 |
| SCHEMBL ID | 860802 |
| MeSH ID | M0582531 |
Synonyms (3)
| Synonym |
|---|
| SCHEMBL860802 |
| fluorocoxib a |
| 5-[4-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]butylcarbamoyl]-2-(3-oxa-23-aza-9-azoniaheptacyclo[17.7.1.15,9.02,17.04,15.023,27.013,28]octacosa-1(27),2(17),4,9(28),13,15,18-heptaen-16-yl)benzoic acid |
Research Excerpts
Overview
Fluorocoxib A is a targeted optical imaging agent. It could be applied for the detection of Cox-2 expressing human bladder cancer.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fluorocoxib A is a targeted optical imaging agent that could be applied for the detection of Cox-2 expressing human bladder cancer." | ( Detection of carcinogen-induced bladder cancer by fluorocoxib A. Bourn, J; Cekanova, M; Donnell, R; Marnett, L; Rathore, K; Uddin, MJ; White, W, 2019) | 2.21 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Blood and urine samples collected three days after administration of each dose of fluorocoxib A revealed no evidence of toxicity, and no clinically relevant adverse events were noted on physical examination of exposed dogs over that time period." | ( Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model. Bartges, JW; Callens, A; Cekanova, M; Galyon, G; Legendre, AM; Marnett, LJ; Martin-Jimenez, T; Uddin, MJ, 2012) | 0.85 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs." | ( Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model. Bartges, JW; Callens, A; Cekanova, M; Galyon, G; Legendre, AM; Marnett, LJ; Martin-Jimenez, T; Uddin, MJ, 2012) | 0.83 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||